<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814642</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_110</org_study_id>
    <nct_id>NCT03814642</nct_id>
  </id_info>
  <brief_title>Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants</brief_title>
  <official_title>A Randomized, Open-label, Three-period, Multiple Dosing Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacodynamics of Clopidogrel According to CYP2C19 Genotypes in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the influence of tegoprazan on the pharmacodynamics of
      clopidogrel according to CYP2C19 genotypes following co-administration of tegoprazan and
      clopidogrel in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation Criteria:

        -  Pharmacodynamic assessments using P2Y12 assay

        -  Safety assessments with adverse event monitoring including subjective/objective
           symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in P2Y12 Reaction Unit (PRU) from baseline</measure>
    <time_frame>Pre-dose(0h) on days 1, 3, 5, and 8 in each period</time_frame>
    <description>Pharmacodynamic blood sampling to measure PRU using VerifyNow® system</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of clopidogrel 75 mg tablet once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg + Tegoprazan 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg + Esomeprazole 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75 mg</intervention_name>
    <description>Clopidogrel 75 mg tablet</description>
    <arm_group_label>Clopidogrel 75 mg</arm_group_label>
    <arm_group_label>Clopidogrel 75 mg + Esomeprazole 20 mg</arm_group_label>
    <arm_group_label>Clopidogrel 75 mg + Tegoprazan 50 mg</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 50 mg</intervention_name>
    <description>Tegoprazan 50 mg tablet</description>
    <arm_group_label>Clopidogrel 75 mg + Tegoprazan 50 mg</arm_group_label>
    <other_name>K-CAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 20 mg</intervention_name>
    <description>Esomeprazole 20 mg tablet</description>
    <arm_group_label>Clopidogrel 75 mg + Esomeprazole 20 mg</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged ≥ 19 years and ≤ 50 years on the date of the written informed
             consent

          -  Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 18.0 kg/m2 and
             ≤ 27.0 kg/m2 at the time of screening

          -  Helicobacter pylori negative

          -  Voluntarily decided to participate in the study and provided written informed consent
             before any screening procedure

          -  Judged by the investigator to be eligible for this study based on physical
             examination, laboratory test, inquiry, etc.

        Exclusion Criteria:

          -  Has a history of or currently has clinically significant liver, kidney, nervous
             system, respiratory system, endocrine system, blood, cardiovascular system, urinary
             system, or psychiatric disease or tumor

          -  Has a history of or currently has gastrointestinal disorder (gastrointestinal ulcer,
             gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease, etc.)
             that may influence the safety and pharmacodynamic assessments of the investigational
             product

          -  Has a history of gastrointestinal surgery (except simple appendectomy and hernia
             surgery)

          -  Hypersensitivity to drugs including the ingredients of the investigational product and
             other drugs (aspirin, antibiotics, etc.) or a history of clinically significant
             hypersensitivity

          -  Positive serological test including hepatitis B, hepatitis C, or human
             immunodeficiency virus (HIV)

          -  Blood total bilirubin, AST (GOT), and ALT (GPT) levels greater than 1.5x of the upper
             limit of normal range at screening

          -  Platelet, PT and aPTT levels outside the upper/lower limit of normal range by 10% at
             screening

          -  P2Y12 Reaction Unit (PRU) by P2Y12 assay outside the upper/lower limit of normal range
             by 10% at screening

          -  *17 allele by CYP2C19 genotyping (Ultrarapid metabolizer)

          -  Systolic blood pressure &lt; 90 mmHg or &gt; 140 mmHg, diastolic blood pressure &lt; 50 mmHg or
             &gt; 95 mmHg, or pulse rate &lt; 45 beats/minute or &gt; 100 beats/minute when vital signs are
             measured in sitting position after resting for at least 5 minutes during screening

          -  QTc &gt; 450 msec, PR interval &gt; 200 msec, QRS interval &gt; 120 msec, and other clinically
             significant findings on electrocardiogram at screening

          -  Has a history of or positive urine screening for drug abuse

          -  Administration of any prescription drugs or herbal medicine within 2 weeks prior to
             the expected date of the first dose, or administration of any over-the-counter (OTC)
             drug, health functional food or vitamin within 1 week prior to the expected date of
             the first dose (However, can participate in the study if otherwise decided eligible by
             the investigator)

          -  Participation in other clinical study or bioequivalence study to receive an
             investigational product within 3 months prior to the expected date of the first dose

          -  Donation of whole blood within 2 months or apheresis/receipt of blood transfusion
             within 1 month prior to the expected date of the first dose

          -  Excessive caffeine intake (&gt; 5 units/day) or persistent alcohol intake (&gt; 21
             units/week, 1 unit = 10 g of pure alcohol), or inability to abstain from drinking
             during hospitalization period

          -  Smoking for more than 3 months prior to the study or inability to cease smoking
             throughout the study

          -  Inability to refrain from grapefruit-containing food from 24 hours before admission to
             discharge

          -  Inability to refrain from caffeine-containing food (coffee, tea (black tea, green tea,
             etc.), carbonated drink, coffee-flavored milk, nutritional tonic, etc.) from 24 hours
             before admission to discharge

          -  Inability to use a medically acceptable method of contraception throughout the study.
             Medically acceptable methods of contraception include use of intrauterine device with
             established failure rate of contraception by spouse (or partner), concomitant use of
             barrier method (for male or for female) and spermicide, or surgical procedure on
             subject himself or his partner (vasectomy, tubal resection/ligation, hysterectomy)

          -  Considered ineligible to participate in the study by the investigator based on
             laboratory test results or other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Dept. of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital, Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

